Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 04, 2026
TickeronGET DAILY SIGNALS
PROCEPT BioRobotics (PRCT) Delivers 18% Revenue Growth in Q3 Despite Slight Miss

PROCEPT BioRobotics (PRCT) Delivers 18% Revenue Growth in Q3 Despite Slight Miss

Key Takeaways

  • PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million, up 18% year over year, but slightly below the consensus estimate of roughly $100.5 million.
  • Net loss per share (EPS, or earnings per share) was $0.46, a larger loss than the $0.39 analysts had expected.
  • U.S. procedure volume climbed 22% to more than 13,400 procedures, driven by strong utilization of the HYDROS robotic system.
  • Management reaffirmed full-year 2026 revenue guidance of $390 million to $410 million and reiterated its goal of positive adjusted EBITDA in the fourth quarter.
  • International revenue reached a record $12.5 million, up 32% year over year.

Why This Quarter Matters to Investors

PROCEPT BioRobotics is a surgical robotics company focused on urology, best known for its HYDROS system and Aquablation therapy, which treats benign prostatic hyperplasia (BPH, an enlarged prostate). This quarterly report matters because it tests whether the company can sustain double-digit procedure growth while simultaneously transitioning its installed base from legacy AquaBeam systems to the newer HYDROS platform. I am watching the path to profitability closely, as management has repeatedly pointed to positive adjusted EBITDA by the fourth quarter of 2026. With procedure volume, system pricing, and gross margin all moving in the right direction, the third-quarter print offers a key read on the durability of the company's commercial momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Breaking Down the Reported Results

For the quarter ended September 30, 2026, PROCEPT BioRobotics reported total revenue of $98.3 million, an 18% increase from $83.3 million in the prior-year period. The figure came in modestly below the consensus estimate of approximately $100.5 million. U.S. revenue rose 16% to $85.8 million, while international revenue grew 32% to a record $12.5 million.

U.S. procedures increased 22% year over year to more than 13,400, and U.S. handpiece and consumable revenue climbed 21% to $53.9 million, supported by a higher handpiece average selling price (ASP) of approximately $3,570. The company shipped 62 HYDROS systems in the quarter, including 20 replacement systems, at a new-system ASP of approximately $495,000.

Gross margin improved to 66% from 65% a year earlier. Operating expenses rose to $92.5 million from $77.2 million, reflecting investment in clinical studies, product development, and sales programs. The net loss widened to $26.5 million, or $0.46 per share, compared with a net loss of $21.4 million, or $0.38 per share, in the prior-year period. Adjusted EBITDA was a loss of $9.8 million, versus a loss of $7.4 million a year ago. Cash, cash equivalents, and restricted cash totaled $221.4 million at quarter-end.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was mixed after the company missed the EPS consensus estimate in the second quarter even as revenue topped expectations. The third-quarter results carried a similar theme: solid top-line growth and healthy procedure momentum, but a bottom-line result that landed slightly below analyst forecasts. The reaffirmation of full-year revenue guidance of $390 million to $410 million and the reiterated commitment to positive adjusted EBITDA in the fourth quarter are likely to be the most closely watched signals for investor confidence. The company's emphasis on pricing discipline, an accelerating HYDROS replacement cycle, and a record international quarter provide supportive context, though the modest revenue and EPS shortfalls may temper near-term enthusiasm.

Forward Outlook and Key Factors to Monitor

Management reiterated its full-year 2026 revenue outlook of $390 million to $410 million, implying 27% to 33% growth versus 2025, and now expects roughly 54,000 U.S. procedures for the year. The company also guided for fourth-quarter gross margin of about 65% and full-year operating expenses of $359 million to $363 million, with adjusted EBITDA expected to turn positive in the fourth quarter.

One key dynamic to watch is the pace of the AquaBeam-to-HYDROS upgrade cycle. Management now expects 50 to 60 replacement system sales in 2026 at an ASP of roughly $315,000, a sign that account conversions are accelerating. Because HYDROS accounts generate meaningfully higher procedure volume than legacy AquaBeam accounts, a faster transition could support stronger recurring revenue over time.

Looking further ahead, management indicated that approximately 20% revenue growth is a reasonable starting point for 2027 planning. Investors should also monitor gross margin trends, handpiece pricing, and international expansion in the United Kingdom and Japan. Finally, the WATER4 clinical trial, which compares Aquablation therapy to radical prostatectomy for prostate cancer, remains a major catalyst, with primary endpoint results expected in May 2027.

Using AI Tools in My Research Process

In my analysis of names like PRCT, I frequently turn to Tickeron's AI Screener for a structured way to filter opportunities based on technical patterns, fundamentals, and performance metrics. It helps surface candidates efficiently and supports a more systematic approach without replacing my own judgment on the numbers and outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PRCT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Aroon Indicator for PRCT shows an upward move is likely

PRCT's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 178 similar instances where the Aroon Indicator showed a similar pattern. In 148 of the 178 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on PRCT as a result. In 75 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

PRCT moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PRCT crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRCT advanced for three days, in 195 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

PRCT broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.473) is normal, around the industry mean (4.142). P/E Ratio (-10.574) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.249) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PRCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
150 Baytech Drive
Phone
+1 650 232-7200
Employees
888
Web
https://www.procept-biorobotics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.